4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (Nasdaq: FDMT) has completed enrollment in all three cohorts of its Phase 1 Dose Exploration clinical trial for 4D-150 in patients with wet AMD, totaling 15 patients. All cohorts reported no dose-limiting toxicities, indicating safety. Interim clinical data from cohort 1 will be released on November 14, 2022, at 7:30 am E.T., followed by a conference call at 8:00 am E.T. The data will cover safety, efficacy, and aflibercept transgene expression. This investigational treatment aims to manage wet AMD, a condition leading to vision loss.

4D Molecular Therapeutics (FDMT) announced its third quarter 2022 financial results, reporting total revenue of $0.5 million, down from $1.4 million in Q3 2021. The net loss increased to $25.7 million from $22.2 million year-over-year. The company highlighted promising interim data from its Phase 1/2 clinical trial of 4D-710 for cystic fibrosis, showing safety and transgene expression in patients. With $239 million in cash and equivalents, FDMT expects to fund operations into the first half of 2025, emphasizing efficient cash utilization.

4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim results from the Phase 1/2 trial of 4D-710 for cystic fibrosis at the NACFC. All three patients in Cohort 1 exhibited 100% successful delivery and expression of the CFTR∆R transgene in lung tissue samples. The treatment was well tolerated with no drug-related adverse events reported. Ongoing enrollment for Cohort 2 is underway, and further data is expected in 2023, highlighting the potential of 4D-710 for patients not eligible for current CFTR modulators.

4D Molecular Therapeutics (Nasdaq: FDMT) will present interim clinical data from its Phase 1/2 trial of 4D-710 at the North American Cystic Fibrosis Conference (NACFC) from November 3-5, 2022. The presentation will cover safety, tolerability, delivery, and CFTR transgene expression in cystic fibrosis patients. Following the presentation, a conference call will be hosted on November 3rd at 4:30 PM ET to discuss results. 4D-710 aims to treat cystic fibrosis via aerosol delivery, potentially benefiting a wide range of patients with various CFTR mutations.

4D Molecular Therapeutics (Nasdaq: FDMT) has appointed Noriyuki Kasahara, MD, PhD to its Board of Directors and promoted Fred Kamal, PhD to President and COO. These leadership changes aim to enhance the company's clinical development of five product candidates targeting ophthalmology, cardiology, and pulmonology. Dr. Kasahara brings over 30 years of expertise in gene therapy, while Dr. Kamal's expanded role reflects a commitment to the company's growth. The five clinical candidates are 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110, although none have FDA approval yet.

4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in two upcoming investor conferences. The first is the Jefferies Cell and Genetic Medicine Summit, featuring a corporate presentation on September 30, 2022, at 9:00 a.m. ET. The second event is Chardan’s 6th Annual Genetic Medicines Conference, where one-on-one meetings will take place on October 3, 2022. A live audio webcast of the presentation will be accessible on the company's website, with a replay available for two weeks post-event. 4DMT specializes in targeted genetic medicines and is advancing five clinical-stage products in various therapeutic areas.

4D Molecular Therapeutics (Nasdaq: FDMT) reported its second quarter 2022 financial results, showing total revenue of $0.2 million, down from $14.6 million in Q2 2021. The company maintained $261.6 million in cash and equivalents, sufficient to fund operations into the first half of 2025. Key developments include the expansion of the eligible patient population for 4D-310's Phase 1/2 trial for Fabry disease to include females. The net loss for the quarter was $28.1 million, compared to $7.6 million in the prior year.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced its participation in two major investor conferences. The company will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 8:00 a.m. ET, followed by a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PT. Investors can access a live audio webcast of these presentations on their website, with replays available for two weeks.

4DMT is focused on targeted genetic medicines using its Therapeutic Vector Evolution platform.

4D Molecular Therapeutics (NASDAQ: FDMT) reported its first quarter 2022 financial results, highlighting key clinical advancements in its pipeline. The firm initiated the treatment of the first patient with 4D-150 for wet AMD and dosed the first patient in a Phase 1/2 trial for 4D-710 targeting cystic fibrosis. Despite these developments, total revenue decreased to $1.2 million from $2.0 million year-over-year. R&D expenses rose to $19.4 million, contributing to a net loss of $26.3 million. The company maintains a strong cash position of $284.5 million, expected to fund operations into 2024.